(Total Views: 457)
Posted On: 06/25/2025 6:56:59 PM
Post# of 154563
Yes , doses were suboptimal , and at this time no patient was on check point inhibitor ,
Our overall survival still double from 7.5 months to 15.8 .
I think our results in CRC trial should be very good .
We know much more right now about the dose , and PD-L1 elevation .
Our overall survival still double from 7.5 months to 15.8 .
I think our results in CRC trial should be very good .
We know much more right now about the dose , and PD-L1 elevation .
(19)
(0)
